fbpx

List – 65 Drug Patents that are Expiring in 2025

In the past, we published a list of drug patents expiring in 2023 and 2024. The list saw tremendous interest from people in the generic pharmaceutical industry.  And why not?

With the explosive growth in the generic drug market, generic companies (like yours) are in a battle to claim a share of the soon-to-be-expired drugs as quickly as possible. You would want to know as much as possible. We totally get it. And keeping that very thought in mind, we collated a list of 65 drugs that are going off-patent in 2025. We also included other information like dosage information, ingredients, and the diseases they cure. This could help you easily choose the most profitable drug to develop a generic version of. 

Loved the idea and the list? Thank us later in the comments section. Now onto the list.

The article has a list of drug patents expiring in 2025. You can get the drug patents expiration list from 2026 to 2030 in a PDF by filling out the form below.


Drug Patents Expiring in 2025

Xalkori
Crizotinib

Sales:
$524 Million (2018)

More information about this Drug

Patents Expiration Date
US8785632 March 01, 2025
US7230098 August 26, 2025
US7858643 October 8, 2029
US8217057 November 6, 2029

Dosage: Capsule; Oral
Company: Pfizer
Ingredients: Crizotinib
Treatment: Non-Small Cell Lung Carcinoma

Omegaven
Fish Oil Triglycerides

Sales:

More information about this Drug

Patents Expiration Date
US9566260 July 11, 2025
US9629821 July 11, 2025
US10350186 November 05, 2024

Dosage: Emulsion; Intravenous
Company: Fresenius Kabi USA LLC
Ingredients: Fish Oil Triglycerides
Treatment: Parenteral Nutrition-Associated Cholestasis (PNAC)

Yupelri
Revefenacin

Sales:
$3.3 Million (Q4, 2018)

More information about this Drug

Patents Expiration Date
US7491736 March 10, 2025
US7521041 March 10, 2025
US7550595 March 10, 2025
US7585879 March 10, 2025
US7910608 March 10, 2025
US7288657 December 23, 2025
US10550081 July 14, 2030
US9765028 July 14, 2030
US8541451 August 25, 2031

Dosage: Solution; Inhalation
Company: Mylan Ireland Ltd
Ingredients: Revefenacin
Treatment: Chronic Obstructive Pulmonary Disease

Sprycel
Dasatinib

Sales:
$2 Billion (2018)

More information about this Drug

Patents Expiration Date
US8680103 February 04, 2025

Dosage: Tablet; Oral
Company: Bristol Myers Squibb Co
Ingredients: Dasatinib
Treatment: Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL)

Bosulif
Bosutinib Monohydrate

Sales:
$477 Million (2019)

More information about this Drug

Patents Expiration Date
US7417148 December 11, 2025
US7767678 November 23, 2026
US7919625 December 11, 2025

Dosage: Tablet; Oral
Company: PF Prism CV
Ingredients: Bosutinib Monohydrate
Treatment: Chronic Phase Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia

Cresemba
Isavuconazonium Sulfate

Sales:
$180 Million (Jul 2018 – Jun 2019)

More information about this Drug

Patents Expiration Date
US6812238 October 31, 2025

Dosage: Capsule; Oral
Company: Astellas Pharma US Inc
Ingredients: Isavuconazonium Sulfate
Treatment: Invasive Aspergillosis And Mucormycosis

Antara
Fenofibrate

Sales:
$70 Million (2008)

More information about this Drug

Patents Expiration Date
US8026281 April 22, 2025

Dosage: Capsule; Oral
Company: Lupin Inc
Ingredients: Fenofibrate
Treatment: High Cholesterol and Triglycerides (fatty acids) in Blood

Section

Lysteda
Tranexamic Acid

Sales:
$25 Million (2012)

More information about this Drug

Patents Expiration Date
US7947739 March 04, 2025
US8022106 March 04, 2025
US8273795 March 04, 2025
US8487005 March 04, 2025
US8791160 March 04, 2025
US8809394 March 04, 2025
US8957113 March 04, 2025
US9060939 March 04, 2025

Dosage: Tablet; Oral
Company: Amring Pharmaceuticals Inc
Ingredients: Tranexamic Acid
Treatment: Cyclic Heavy Menstrual Bleeding

Bepreve
Bepotastine Besilate

Sales:
$160.3 Million (2011)

More information about this Drug

Patents Expiration Date
US8784789 January 13, 2025
US8877168 July 30, 2023

Dosage: Solution/Drops; Ophthalmic
Company: Bausch And Lomb Inc
Ingredients: Bepotastine Besilate
Treatment: Itching of the Eyes due to Allergies

Sancuso
Granisetron

Sales:
$20 – $25 Million

More information about this Drug

Patents Expiration Date
US7608282 January 22, 2025

Dosage: Film, Extended Release; Transdermal
Company: Kyowa Kirin Inc
Ingredients: Granisetron
Treatment: Nausea and Vomiting Caused by Cancer Chemotherapy

Nucynta
Tapentadol Hydrochloride

Sales:
$46.8 Million (2019)

More information about this Drug

Patents Expiration Date
US7994364 June 27, 2025

Dosage: Tablet; Oral
Company: Collegium Pharmaceuticals Inc
Ingredients: Tapentadol Hydrochloride
Treatment: Moderate to Severe Pain

Nexlizet
Bempedoic Acid, Ezetimibe

Sales:

More information about this Drug

Patents Expiration Date
US7335799 December 03, 2025

Dosage: Tablet; Oral
Company: Esperion Therapeutics Inc
Ingredients: Bempedoic Acid, Ezetimibe
Treatment: Reduce the Amount of Cholesterol and other Fatty Substances in Blood

Vyzulta
Latanoprostene Bunod

Sales:

More information about this Drug

Patents Expiration Date
US8058467 January 5, 2025
US7910767 January 5, 2025
US7273946 October 3, 2025

Dosage: Eye Drops
Company: Bausch & Lomb
Ingredients: LATANOPROSTENE BUNOD
Treatment: Intraocular Pressure in Patients with Open-angle Glaucoma or Ocular Hypertension

Trilipix
Fenofibrate

Sales:

More information about this Drug

Patents Expiration Date
US7259186 January 7, 2025

Dosage: Oral
Company: AbbVie Inc
Ingredients: CHOLINE FENOFIBRATE
Treatment: Abnormal Blood Lipid Levels

Duaklir
Aclidinium bromide/formoterol

Sales:

More information about this Drug

Patents Expiration Date
USRE46417 February 10, 2025

Dosage: Inhalation
Company: ALMIRALL, S.A
Ingredients: ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE
Treatment: Chronic Obstructive Pulmonary Disease (COPD)

Arcapta
Indacaterol

Sales:

More information about this Drug

Patents Expiration Date
US6878721 February 25, 2025

Dosage: Inhalation
Company: Novartis
Ingredients: INDACATEROL MALEATE
Treatment: Chronic Obstructive Pulmonary Disease (COPD)

Rukobia
Fostemsavir

Sales:

More information about this Drug

Patents Expiration Date
US8461333 February 25, 2025
US7745625 November 19, 2027

Dosage: Oral
Company: ViiV Healthcare
Ingredients: FOSTEMSAVIR TROMETHAMINE
Treatment: HIV/AIDS

Incivek
Telaprevir

Sales:

More information about this Drug

Patents Expiration Date
US7820671 February 25, 2025

Dosage: Oral
Company: Johnson & Johnson
Ingredients: TELAPREVIR
Treatment: Hepatitis C

Viberzi
Eluxadoline

Sales:

More information about this Drug

Patents Expiration Date
US10213415 March 14, 2025
US8609709 March 14, 2025
US7786158 March 14, 2025
US9115091 July 7, 2028
US8691860 July 7, 2028
US7741356 May 27, 2029

Dosage: Oral
Company: Allergan
Ingredients: ELUXADOLINE
Treatment: Diarrhea and Abdominal Pain

Glucophage
Metformin

Sales:

More information about this Drug

Patents Expiration Date
US7780987 March 23, 2025

Dosage: Oral
Company: Merck & Co
Ingredients: METFORMIN HYDROCHLORIDE
Treatment: Type 2 Diabetes

Roxicodone
Oxycodone

Sales:

More information about this Drug

Patents Expiration Date
US10696684 March 30, 2025
US10407434 March 30, 2025
US9522919 March 30, 2025
US9073933 March 30, 2025

Dosage: Oral, Sublingual, Intramuscular, Intravenous, Intranasal, Subcutaneous, Transdermal, Rectal, Epidural
Company: Xanodyne Pharmaceuticals
Ingredients: OXYCODONE HYDROCHLORIDE
Treatment: Moderate to Severe Pain

Tegsedi
Inotersen

Sales:

More information about this Drug

Patents Expiration Date
US8101743 April 1, 2025
US9061044 April 29, 2031

Dosage: Subcutaneous injection
Company: Akcea Therapeutics, Inc.
Ingredients: INOTERSEN SODIUM
Treatment: Nerve Damage in adults with Hereditary transthyretin-mediated Amyloidosis

Reyvow
Lasmiditan

Sales:

More information about this Drug

Patents Expiration Date
US7423050 April 6, 2025
US11053214 December 5, 2037

Dosage: Oral, Intravenous
Company: Eli Lilly and Company
Ingredients: LASMIDITAN SUCCINATE
Treatment: Migraine with or without Aura

Kyprolis
Carfilzomib

Sales:
$1.06 Billion (2020)

More information about this Drug

Patents Expiration Date
US8207125 April 14, 2025
US7232818 April 14, 2025
US8207297 April 14, 2025
US7417042 July 20, 2026

Dosage: Intravenous
Company: Amgen Inc.
Ingredients: CARFILZOMIB
Treatment: Relapsed or Refractory Multiple Myeloma

Biktarvy
Bictegravir/emtricitabine/tenofovir alafenamide

Sales:

More information about this Drug

Patents Expiration Date
US7390791 April 17, 2025
US9296769 August 15, 2032
US8754065 August 15, 2032
US9216996 December 19, 2033
US9732092 December 19, 2033
US9708342 June 19, 2035

Dosage: Oral
Company: Gilead Sciences
Ingredients: BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Treatment: HIV/AIDS

Stendra
Avanafil

Sales:

More information about this Drug

Patents Expiration Date
US6656935 April 27, 2025

Dosage: Oral
Company: Vivus Inc.
Ingredients: AVANAFIL
Treatment: Erectile Dysfunction

Inlyta
Axitinib

Sales:
$93 Million (2020)

More information about this Drug

Patents Expiration Date
US6534524 April 29, 2025
US8791140 December 14, 2030

Dosage: Oral
Company: Pfizer
Ingredients: AXITINIB
Treatment: Renal Cell Carcinoma

Camptosar
Irinotecan

Sales:

More information about this Drug

Patents Expiration Date
US9782349 May 2, 2025
US9724303 May 2, 2025
US8992970 May 2, 2025
US10722508 May 2, 2025
US8329213 January 6, 2027
US8147867 August 29, 2028

Dosage: Intravenous
Company: Pfizer
Ingredients: IRINOTECAN HYDROCHLORIDE
Treatment: Colon Cancer and Small Cell Lung Cancer

Jentadueto
Linagliptin/metformin hydrochloride

Sales:

More information about this Drug

Patents Expiration Date
US7407955 May 2, 2025

Dosage: Oral
Company: Boehringer Ingelheim
Ingredients: LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Treatment: High Blood Sugar Levels caused by Type 2 Diabetes

Pexeva
Paroxetine mesylate

Sales:

More information about this Drug

Patents Expiration Date
US7598271 May 4, 2025
US8946251 August 4, 2026
US8658663 April 6, 2029

Dosage: Oral
Company: Sebela Pharmaceutical
Ingredients: PAROXETINE MESYLATE
Treatment: Symptoms of Menopause

Doptelet
Avatrombopag

Sales:

More information about this Drug

Patents Expiration Date
US7638536 May 5, 2025

Dosage: Oral
Company: AkaRx, Inc.
Ingredients: AVATROMBOPAG MALEATE
Treatment: Thrombocytopenia Associated with Chronic Liver Disease

Lymphoseek
Technetium Tc 99m tilmanocept

Sales:

More information about this Drug

Patents Expiration Date
US6409990 May 12, 2025
US9439985 September 27, 2033

Dosage: Subcutaneous injection
Company: Navidea Biopharmaceuticals
Ingredients: TECHNETIUM TC-99M TILMANOCEPT
Treatment: Identify Sentinel Lymph Nodes

Olysio
Simeprevir

Sales:

More information about this Drug

Patents Expiration Date
US7671032 May 19, 2025
US8349869 July 28, 2026
US8754106 July 28, 2026
US8741926 July 28, 2026
US9040562 July 28, 2026
US9856265 July 28, 2026
US8148399 September 5, 2029

Dosage: Oral
Company: Johnson & Johnson
Ingredients: SIMEPREVIR SODIUM
Treatment: Hepatitis C

Edarbi
Azilsartan

Sales:

More information about this Drug

Patents Expiration Date
US7157584 May 22, 2025

Dosage: Oral
Company: Takeda Pharmaceutical
Ingredients: AZILSARTAN KAMEDOXOMIL
Treatment: Hypertension

Onpattro
Patisiran

Sales:

More information about this Drug

Patents Expiration Date
US8334373 May 27, 2025
US8168775 October 20, 2029
US10240152 October 20, 2029
US11079379 August 27, 2035

Dosage: Intravenous
Company: Alnylam Pharmaceuticals
Ingredients: PATISIRAN SODIUM
Treatment: Polyneuropathy in People with Hereditary transthyretin-mediated Amyloidosis

Diprivan
Propofol

Sales:

More information about this Drug

Patents Expiration Date
US8476010 June 1, 2025

Dosage: Intravenous
Company: Fresenius Kabi
Ingredients: PROPOFOL
Treatment: Used to help Patients Relax before and during General Anesthesia for Surgery

Kazano
Alogliptin/metformin

Sales:

More information about this Drug

Patents Expiration Date
US8288539 June 24, 2025
US7807689 June 27, 2028

Dosage: Oral
Company: Takeda Pharmaceuticals
Ingredients: ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE
Treatment: Blood Sugar Control in Adults with Type 2 Diabetes

Amondys 45
Casimersen

Sales:

More information about this Drug

Patents Expiration Date
US9447415 June 28, 2025
US8524880 April 2, 2026
US10287586 November 12, 2030
US9228187 November 12, 2030

Dosage: Intravenous
Company: Sarepta Therapeutics, Inc.
Ingredients: CASIMERSEN
Treatment: Duchenne Muscular Dystrophy (DMD)

Exondys 51
Eteplirsen

Sales:

More information about this Drug

Patents Expiration Date
US10781451 June 28, 2025
US9018368 June 28, 2025
US9243245 October 27, 2028

Dosage: Intravenous
Company: Sarepta Therapeutics, Inc.
Ingredients: ETEPLIRSEN
Treatment: Duchenne Muscular Dystrophy (DMD)

Vyondys 53
Golodirsen

Sales:

More information about this Drug

Patents Expiration Date
US10227590 June 28, 2025
US9994851 June 28, 2025
US9024007 June 28, 2025
US10968450 June 28, 2025
US10421966 June 28, 2025

Dosage: Intravenous
Company: Sarepta Therapeutics, Inc.
Ingredients: GOLODIRSEN
Treatment: Duchenne Muscular Dystrophy (DMD)

Vyleesi
Bremelanotide

Sales:

More information about this Drug

Patents Expiration Date
US6794489 June 28, 2025

Dosage: Subcutaneous
Company: Palatin Technologies
Ingredients: BREMELANOTIDE ACETATE
Treatment: Low Sexual Desire in Women

Zydelig
Idelalisib

Sales:

More information about this Drug

Patents Expiration Date
USRE44638 August 5, 2025
US8865730 March 5, 2033
US10730879 March 5, 2033
US9469643 September 2, 2033

Dosage: Oral
Company: Gilead Sciences
Ingredients: IDELALISIB
Treatment: Blood Cancer

Duzallo
Lesinurad/Allopurinol

Sales:

More information about this Drug

Patents Expiration Date
US8003681 August 25, 2025
US8546436 February 29, 2032

Dosage: Oral
Company: AstraZeneca
Ingredients: ALLOPURINOL; LESINURAD
Treatment: Gout

Prolensa
Bromfenac

Sales:

More information about this Drug

Patents Expiration Date
US8129431 September 11, 2025

Dosage: Eye Drops
Company: Bausch & Lomb
Ingredients: BROMFENAC SODIUM
Treatment: Ocular Inflammation and Pain after Cataract Surgery

Nuplazid
Pimavanserin

Sales:

More information about this Drug

Patents Expiration Date
US7923564 September 26, 2025
US7732615 June 3, 2028
US7601740 April 29, 2030

Dosage: Oral
Company: Acadia Pharmaceuticals
Ingredients: PIMAVANSERIN TARTRATE
Treatment: Parkinson’s disease psychosis

Baxdela
Delafloxacin

Sales:

More information about this Drug

Patents Expiration Date
US9539250 October 7, 2025
US8273892 August 6, 2026
US7728143 November 20, 2027
US8871938 September 23, 2029
USRE46617 December 28, 2029

Dosage: Oral, Intravenous
Company: Melinta Therapeutics
Ingredients: DELAFLOXACIN MEGLUMINE
Treatment: Acute Bacterial Skin and Skin Structure Infections

Lenvima
Lenvatinib

Sales:

More information about this Drug

Patents Expiration Date
US7253286 October 24, 2025
US7612208 September 19, 2026
US11186547 August 26, 2035
US10407393 August 26, 2035
US10259791 August 26, 2035

Dosage: Oral
Company: Eisai Inc
Ingredients: LENVATINIB MESYLATE
Treatment: Thyroid Cancer

Cresemba
Isavuconazole

Sales:

More information about this Drug

Patents Expiration Date
US6812238 October 31, 2025

Dosage: Oral, Intravenous
Company: Astellas Pharma
Ingredients: ISAVUCONAZONIUM SULFATE
Treatment: Aspergillosis and Mucormycosis

Lybalvi
Olanzapine/samidorphan

Sales:

More information about this Drug

Patents Expiration Date
US7262298 November 23, 2025
US9119848 August 30, 2031

Dosage: Oral
Company: Alkermes, Inc
Ingredients: OLANZAPINE; SAMIDORPHAN L-MALATE
Treatment: Schizophrenia and Bipolar Disorder

Opsumit
Macitentan

Sales:

More information about this Drug

Patents Expiration Date
US7094781 December 5, 2025

Dosage: Oral
Company: Actelion Pharmaceuticals
Ingredients: MACITENTAN
Treatment: Pulmonary Arterial Hypertension

Latuda
Lurasidone

Sales:

More information about this Drug

Patents Expiration Date
USRE45573 December 23, 2025

Dosage: Oral
Company: Sunovion Pharmaceuticals
Ingredients: LURASIDONE HYDROCHLORIDE
Treatment: Schizophrenia and Bipolar Disorder

Klisyri
Tirbanibulin

Sales:

More information about this Drug

Patents Expiration Date
US8980890 December 28, 2025
US8236799 December 28, 2025
US7300931 February 6, 2026
US7851470 February 2, 2029
US10669236 September 7, 2038

Dosage: Topical
Company: Almirall, LLC.
Ingredients: TIRBANIBULIN
Treatment: Actinic Keratosis

Signifor
Pasireotide

Sales:

More information about this Drug

Patents Expiration Date
US8299209 December 27, 2025
US7473761 December 14, 2026

Dosage: Subcutaneous Injection, Intramuscular Injection
Company: Recordati Rare Diseases Inc.
Ingredients: PASIREOTIDE DIASPARTATE
Treatment: Cushing’s Disease

Conclusion

As a drug patent expires it expands the gateway for a number of competitors to enter the market. Tracking these patent expirations beforehand can not only help evaluate business opportunities but also help in refining market entry strategies. But there still lies legal as well as technology threats and hurdles that a generic company will face depending on the drug they choose for the generic version. 

With proper research and threat analysis, developing a generic version wouldn’t be as terrifying. How to go about it? Well, let’s start with getting in touch by filling the form below and we’ll get back to you in no time.


Authored by: Divya Goyal, Team Lead, Life Science Team, and Madan Ekhande, Research Analyst, Life Science Team

Leave a Comment

Become a part of GreyB’s insider list

Get our distilled learning delivered to you.

Get the Sample Report

Fill out the form and get the report.